A.n.n.(@fireflyann) 's Twitter Profileg
A.n.n.

@fireflyann

volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts
https://t.co/48vU5493pH

ID:46803856

linkhttps://www.facebook.com/groups/208490666601307/ calendar_today13-06-2009 02:16:26

18,8K Tweets

1,4K Followers

3,2K Following

Johnathan Ebben MD, PhD(@JohnEbbenMDPhD) 's Twitter Profile Photo

#TumorBoardTuesday Mike Pishvaian Integrity CE Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 15.5/17
🔑 takeaways:
✅Mutant KRAS is now 🎯 in multiple ways
G12C, G12D specific inhib
‼️Pan G12 mutant inhib

Combos w EGFRi & maybe IO may deliver even better responses--more trials needed. Will we need other combos to overcome harsh microenvironment?

account_circle
Johnathan Ebben MD, PhD(@JohnEbbenMDPhD) 's Twitter Profile Photo

#TumorBoardTuesday Mike Pishvaian Integrity CE Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 14/17
Mini 🐦orial 10👨🏽‍🏫

Totally different MOA
RMC 6236 is like a GLUE
Sticks one protein, cyclophilin A, directly onto GTP bound (active) mKRAS.
Similar strat also being used to target KRAS G12C!

The result in PDAC:
Phase I- ORR 20% w some ongoing responses

@TumorBoardTues @MPishvaian @IntegrityCE @DrShubhamPant @PanCAN @lustgartenfdn @kevansf @NEJM @UCSFCancer @KRASKickers 14/17 #TumorBoardTuesday Mini 🐦orial 10👨🏽‍🏫 Totally different MOA RMC 6236 is like a GLUE Sticks one protein, cyclophilin A, directly onto GTP bound (active) mKRAS. Similar strat also being used to target KRAS G12C! The result in PDAC: Phase I- ORR 20% w some ongoing responses
account_circle
Johnathan Ebben MD, PhD(@JohnEbbenMDPhD) 's Twitter Profile Photo

#TumorBoardTuesday Mike Pishvaian Integrity CE Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 11/17
👨🏽‍🏫Mini Tweetorial 7👨🏽‍🏫

What about the rest of the (more common) KRAS mutations?

Lots of work ongoing now, including inhibitors targeting other muts, including more common mutations found in

🔹G12D specific
🔹Pan exon 12
🔹KRAS “on” inhibitors

account_circle
Johnathan Ebben MD, PhD(@JohnEbbenMDPhD) 's Twitter Profile Photo

#TumorBoardTuesday Mike Pishvaian Integrity CE 5/17
👨🏽‍🏫Mini Tweetorial 1👨🏽‍🏫
🧬RAS mutation drives 90+% of
Most common mutation is G12D or G12V, but a minority of patients have G12C (~3%)

💡In non-RAS mutated disease, higher probability of a gene fusion event as a driver

pubmed.ncbi.nlm.nih.gov/28810144/

@TumorBoardTues @MPishvaian @IntegrityCE 5/17 #TumorBoardTuesday 👨🏽‍🏫Mini Tweetorial 1👨🏽‍🏫 🧬RAS mutation drives 90+% of #PDAC Most common mutation is #KRAS G12D or G12V, but a minority of patients have G12C (~3%) 💡In non-RAS mutated disease, higher probability of a gene fusion event as a driver pubmed.ncbi.nlm.nih.gov/28810144/
account_circle
#TumorBoardTuesday(@TumorBoardTues) 's Twitter Profile Photo


🏃We are gaining ground in the chase for the most elusive🎯in cancer💜

📢Join us Tuesday, 03/26/2024 at 8PM ET as Mike Pishvaian & Johnathan Ebben MD, PhD🗣️KRAS targeted therapy as a treatment for

#TumorBoardTuesday 🏃We are gaining ground in the chase for the most elusive🎯in cancer💜 📢Join us Tuesday, 03/26/2024 at 8PM ET as @MPishvaian & @JohnEbbenMDPhD🗣️KRAS targeted therapy as a treatment for #PancreaticCancer
account_circle
GI Oncology Now(@GiOncNow) 's Twitter Profile Photo

that patients with who have enlarged lateral have a higher risk of lateral local recurrence?

A new study has determined the prognostic value of LLN size and malignant features in advanced rectal cancer.

Learn more: buff.ly/4cwfIMG

#DidYouKnow that patients with #rectalcancer who have enlarged lateral #lymphnodes have a higher risk of lateral local recurrence? A new study has determined the prognostic value of LLN size and malignant features in advanced rectal cancer. Learn more: buff.ly/4cwfIMG
account_circle
A.n.n.(@fireflyann) 's Twitter Profile Photo

Onvansertib trial has expanded to more US locations

(AZ, CA, FL, HA, IN, KS, MN, MO, NV, OH, UT, VA)

NCT06106308

Onvansertib trial has expanded to more US locations (AZ, CA, FL, HA, IN, KS, MN, MO, NV, OH, UT, VA) NCT06106308
account_circle
Cardiff Oncology(@CardiffOncology) 's Twitter Profile Photo

Cardiff Oncology will present 5 posters at . They offer an overview of onvansertib's potential in RAS-mutant & RAS-wild type , & .
For more details, visit ow.ly/lwot50QNLfP
Full abstracts are on AACR Online Program.

Cardiff Oncology will present 5 posters at #AACR24. They offer an overview of onvansertib's potential in RAS-mutant & RAS-wild type #mCRC, #smallcelllungcancer & #ovariancancer. For more details, visit ow.ly/lwot50QNLfP Full abstracts are on @AACR Online Program.
account_circle
A.n.n.(@fireflyann) 's Twitter Profile Photo

A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients (EOrOS)
Istituto Clinico Humanitas, Italy
PI: Antonino Spinelli, MD, PhD

NCT06326879
classic.clinicaltrials.gov/ct2/show/NCT06…

A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients (EOrOS) Istituto Clinico Humanitas, Italy PI: Antonino Spinelli, MD, PhD NCT06326879 classic.clinicaltrials.gov/ct2/show/NCT06…
account_circle
Mark Lewis(@marklewismd) 's Twitter Profile Photo

Having long since waived my own confidentiality I know it's a decision you can only make once -- a bell that cannot be unrung -- and also that a patient's privacy is as close to sacrosanct as anything we have in secular medicine, *crucial* to the trust placed in us as physicians

account_circle